Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.38 |
| ▸ | PSMG3 | Q9BT73 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473151 | 0.82 | CYP3A4 (0.38) | CYP3A4PREPCELA1POLBKDM4E | |
| SCHEMBL16666701 | 0.82 | CYP3A4 (0.52) | CYP3A4PSMG3POLBMAPTHPGD | |
| SCHEMBL9507056 | 0.80 | LMNA (0.44) | PREPCELA1POLBKDM4EHTT | |
| SCHEMBL13134484 | 0.78 | LMNA (0.42) | PREPCELA1POLBKDM4EHTT | |
| SCHEMBL14086476 | 0.75 | HTT (0.54) | PREPCELA1POLBKDM4EHTT | |
| SCHEMBL9532473 | 0.75 | CYP3A4 (0.47) | CYP3A4KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL5838924 | 0.75 | CYP3A4 (0.47) | CYP3A4KDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL5865884 | 0.75 | LMNA (0.44) | PREPCELA1POLBKDM4EHTT | |
| SCHEMBL8821099 | 0.74 | PREP (0.42) | CYP3A4PREPCELA1POLBKDM4E | |
| SCHEMBL26797236 | 0.73 | CYP3A4 (0.48) | CYP3A4KDM4EHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815809-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of phenols or thiophenols | DSM IP ASSETS B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| EP-3016940-B1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP ASSETS BV (NL) | 2017-04-12 | — | — | EP | disclosed |
| US-20160168111-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP ASSETS B.V. (NL) | 2016-06-16 | — | — | US | disclosed |
| EP-3016940-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP Assets B.V. (NL) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001029-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP ASSETS B.V. (NL) | 2015-01-08 | — | — | WO | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| CN-101115734-A | Spiro derivatives as lipoxygenase inhibitors | LILLY CO ELI (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-5972959-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0708098-B1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1999-03-03 | — | — | EP | disclosed |
| US-5780490-A | A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS | SANKYO COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5703096-A | ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0708098-A1 | Oxime derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0139421-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-04-27 | — | — | EP | disclosed |
| US-4572912-A | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-02-25 | — | — | US | disclosed |
| EP-0139421-A1 | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168111-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | CYP4B1, CYP4F3, CYP4F2 | CYP3A4 6/4885PREP 2032/4885CELA1 1103/4885 |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | CYP3A4 317/4885PREP 1528/4885CELA1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.